Atlas Trials

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Clinical trial NCT06434597 · RECRUITING

Trial details

NCT number
NCT06434597
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Start date
2024-07-17
Primary completion
2026-12-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.